In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Study efficacy measures will include the expression of dystrophin protein and motor function.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
Subscribe To Our Newsletter & Stay Updated
